CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0002625: Deep venous thrombosisHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (12)


Name (Synonyms) Correlation
drug1012 Enoxaparin/Lovenox Intermediate Dose Wiki 0.32
drug27 2019-nCoV IgG/IgM Rapid Test Cassette Wiki 0.32
drug2275 Public space exposure Wiki 0.32
drug936 Duplex ultrasound and Computed Tomography Angiography Wiki 0.32
drug1010 Enoxaparin Prophylactic Dose Wiki 0.32
drug1009 Enoxaparin Prefilled Syringe [Lovenox] Wiki 0.32
drug1239 Heparin Infusion Wiki 0.32
drug881 Diagnostic examination for venous thromboembolism Wiki 0.32
drug1240 Heparin SC Wiki 0.32
drug914 Doppler Echo Wiki 0.32
drug1007 Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml Wiki 0.32
drug1004 Enoxaparin Wiki 0.09

Correlated MeSH Terms (15)


Name (Synonyms) Correlation
D020246 Venous Thrombosis NIH 1.00
D013927 Thrombosis NIH 0.69
D054556 Venous Thromboembolism NIH 0.48
D011655 Pulmonary Embolism NIH 0.44
D013923 Thromboembolism NIH 0.42
D004617 Embolism NIH 0.42
D013924 Thrombophlebitis NIH 0.32
D016769 Embolism and Thrombosis NIH 0.18
D054058 Acute Coronary Syndrome NIH 0.14
D009205 Myocarditis NIH 0.11
D009203 Myocardial Ischemia NIH 0.09
D016638 Critical Illness NIH 0.04
D014777 Virus Diseases NIH 0.04
D045169 Severe Acute Respiratory Syndrome NIH 0.02
D018352 Coronavirus Infections NIH 0.01

Correlated HPO Terms (5)


Name (Synonyms) Correlation
HP:0002204 Pulmonary embolism HPO 0.44
HP:0001907 Thromboembolism HPO 0.38
HP:0004418 Thrombophlebitis HPO 0.32
HP:0012819 Myocarditis HPO 0.11
HP:0001658 Myocardial infarction HPO 0.09

There are 10 clinical trials

Clinical Trials


1 Screening of Cardiovascular Complications in Patients With COVID-19

Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.

NCT04335162 COVID Acute Coronary Syndrome Myocardial Infarction Myocarditis Venous Thromboembolism Deep Vein Thrombosis Pulmonary Embolism
MeSH:Pulmonary Embolism Myocardial Infarction Thrombosis Acute Coronary Syndrome Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis Myocarditis
HPO:Deep venous thrombosis Myocardial infarction Myocarditis Pulmonary embolism Thromboembolism Venous thrombosis

Primary Outcomes

Description: Incidence of cardiomyopathies and/or venous thromboembolism at day 28

Measure: Determine the incidence of cardiomyopathies and venous thromboembolism

Time: 28 days

Secondary Outcomes

Description: Incidence of mortality at day 28

Measure: Mortality

Time: 28 days

Description: Number of day of using mechanical ventilation for each patients

Measure: Duration of mechanical ventilation

Time: 28 days

Description: Incidence of shock at day 28

Measure: shock at day 28

Time: 28 days

Description: Number of day in intensive care unit

Measure: length of stay in the intensive care unit

Time: 28 days

2 COVID-19 and Deep Venous Thrombosis: a Cross-sectional Study

The aim of this study is to investigate the prevalence and possible risk factors of the occurrence of a DVT in 12 intubated and mechanically ventilated COVID-19 patients admitted to the ICU at a single time point (29/03/2020).

NCT04338932 COVID-19 Deep Vein Thrombosis (DVT)/Thrombophlebitis
MeSH:Thrombosis Venous Thrombosis Thrombophlebitis
HPO:Deep venous thrombosis Thrombophlebitis Venous thrombosis

Primary Outcomes

Description: to investigate the prevalence of a DVT in patients at the ICU.

Measure: the prevalence of a DVT in patients at the ICU.

Time: 1 day at ICU

Secondary Outcomes

Description: evaluate pO2 and pCO2 (mmHg) in patients with and without a DVT

Measure: Oxygen partial pressure and Carbon dioxide partial pressure levels in the blood

Time: 1 day at ICU

Description: evaluate Potassium, Sodium, Calcium, Bicarbonate, Base excess, Lactate levels (mmol/l) in patients with and without a DVT

Measure: Potassium, Sodium, Calcium, Bicarbonate, Base excess, Lactate levels in the blood

Time: 1 day at ICU

Description: evaluate glucose, haemoglobin, ureum, creatinine, total bilirubin levels (mg/dl) in patients with and without a DVT

Measure: glucose, haemoglobin, ureum, creatinine, total bilirubin levels in the blood

Time: 1 day at ICU

Description: evaluate oxygen saturation, basophils, eosinophils, monocytes, neutrophils, haematocrit and prothrombine levels in the blood (%) in patients with and without a DVT

Measure: oxygen saturation, basophils, eosinophils, monocytes, neutrophils, haematocrit and prothrombine levels in the blood

Time: 1 day at ICU

Description: evaluate white blood cells (x 10*9/L), red blood cells (x 10*12/L) and platelets levels (x 109/L) in the blood in patients with and without a DVT

Measure: white blood cells, red blood cells and platelets in the blood

Time: 1 day at ICU

Description: evaluate PT (%)aPTT (sec)Fibrinogen (g/L)D-dimers (mg/L) PT (INR) (ratio) AST (U/L)ALT (U/L)Lactate dehydrogenase (U/L)Troponin T (ng/L)CRP (mg/L)Ferritin (mg/L) in the blood in patients with and without a DVT

Measure: PT (%)aPTT (sec)Fibrinogen (g/L)D-dimers (mg/L) PT (INR) (ratio) AST (U/L)ALT (U/L)Lactate dehydrogenase (U/L)Troponin T (ng/L)CRP (mg/L)Ferritin (mg/L)in the blood

Time: 1 day at ICU

Description: revalence of co morbidities such as Cardiovascular disease, n (%) Hypertension, n (%) Diabetes, n (%) Respiratory disease, n (%) Malignancy, n (%) Chronic renal disease, n (%) Chronic liver disease, n (%) Chronic bowel disease, n (%) Chronic nerve disease, n (%) Cerebrovascular disease, n (%) HIV/AIDS, n (%) Haematological disease, n (%) Obesity, n (%) Rheumatological disease, n (%) Dementia, n (%) in patients with and without a DVT admitted at the ICU in 1 day

Measure: prevalence of co-morbidities

Time: 1 day at ICU

Description: prevalence of vital signs such Temperature (°C) Breathing rate (#/min) Systolic blood pressure (mmHg) Mean arterial blood pressure (mmHg) Heart rate (#/min) Glasgow Coma Scale in patients with and without a DVT

Measure: prevalence of vital signs at icu admission

Time: at ICU admission

Description: prevalance of complications such as ARDS Acute kidney failure Acute heart failure Septic shock Secondary infection Seizure Stroke Hyperglaecemia Hypoglaecemia during ICU stay in patients with and without DVT

Measure: prevalence of complications during icu stay

Time: from ICU admission to cross sectional moment (29/3/2020)

Description: evaluation of treatment such as Antiviral treatment Antibiotic treatment Antifungal treatment Corticosteroid treatment CRRT IVIg treatment Plaquenil treatment during ICU stay in patients with and without DVT

Measure: evaluation of treatment

Time: from ICU admission to cross sectional moment (29/3/2020)

Description: evaluation of the oxygen therapy such as Invasive mechanical ventilation FiO2 (mmHg) PEEP Length of ventilationA ECMO Invasive mechanical ventilation + ECMO Vasopressor/inotropic support Neuromuscular blocking agents Prone ventilation in patients with and without DVT

Measure: evaluation of the oxygen therapy

Time: from ICU admission to cross sectional moment (29/3/2020)

3 COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial

The purpose of this study is to evaluate the safety, dose-requirements, and exploratory efficacy of twice-daily subcutaneous enoxaparin as venous thromboembolism prophylaxis in children (birth to 18 years) hospitalized with signs and/or symptoms of SARS-CoV-2 infection (i.e., COVID-19).

NCT04354155 Infection Viral Thromboses, Venous COVID-19 Drug: Enoxaparin Prefilled Syringe [Lovenox]
MeSH:Thrombosis Venous Thrombosis Virus Diseases
HPO:Deep venous thrombosis Venous thrombosis

Primary Outcomes

Description: To investigate the safety of in-hospital thromboprophylaxis with twice-daily low-dose enoxaparin thromboprophylaxis as measured by cumulative incidence of ISTH-defined clinically-relevant bleeding events during hospitalization. Clinically relevant bleeding episodes may include any of the following: 1) fatal bleeding; 2) clinically overt bleeding associated with a decline in hemoglobin of ≥2g/dL in a 24h period; 3) retroperitoneal, pulmonary, or central nervous system bleeding; 4) bleeding requiring surgical intervention in an operating suite; 5) bleeding for which a blood product is administered (blood product administration not directly attributable to the patient's underlying condition); 6) bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating suite.

Measure: Safety of in-hospital thromboprophylaxis

Time: Day 30

Secondary Outcomes

Description: The median twice-daily enoxaparin dose, as measured in mg/kg, required to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL in children hospitalized with COVID-19, and to compare dose-requirements by age group (birth to <1 year old, 1-<6 years old, 6-<13 years old, and 13-<18 years old).

Measure: Median twice-daily enoxaparin dose

Time: 4 hours post initial dose

Other Outcomes

Description: To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by the proportion of serial D-dimer levels obtained at standardized time points that are <2 times the upper limit of normal (<2x ULN) values for age.

Measure: Efficacy of in-hospital thromboprophylaxis as measured by the proportion of serial D-dimer levels

Time: Enrollment, Day 1, Day 2, and Day 3, 7, and 14 if still hospitalized

Description: To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by confirmed HA-VTE.

Measure: Efficacy of in-hospital thromboprophylaxis as measured by confirmed HA-VTE

Time: Day 30

Description: To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by median duration of in-hospital increased respiratory support (new requirement for high-flow nasal cannula, non-invasive ventilation, and/or mechanical ventilation, relative to any at-home baseline requirement).

Measure: Efficacy of in-hospital thromboprophylaxis as measured by median duration of increased respiratory support

Time: Day 30

4 Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU

The main objective of the study is to determine the incidence of deep vein thromboses at Doppler echo in patients with SARS-Cov-2 pneumopathy upon their entry into ICU and after 7 days of hospitalization in ICU. This is a monocentric interventional study (RIPH 2).

NCT04363528 Deep Vein Thrombosis Other: Doppler Echo
MeSH:Thrombosis Venous Thrombosis
HPO:Deep venous thrombosis Venous thrombosis

Primary Outcomes

Description: Deep vein thrombosis at Doppler echo

Measure: Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU

Time: Day 0

Description: Deep vein thrombosis at Doppler echo

Measure: Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU

Time: Day 7

5 Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID)

This study is being conducted to assess the effectiveness of intermediate versus prophylactic doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the intensive care units (ICUs) throughout the hospital. Anticoagulation is part of the patient's usual standard of care but determining the dose of anticoagulation is based on physician preference. The investigators are conducting this study (a randomized trial with adaptive design employing cluster randomization) with the support of all of the ICUs to collect data in order to determine what should be the standard of care in terms of anticoagulation in these critically ill patients. The patients care will not be altered other than the choice of anticoagulation (both approved and used throughout the hospital as standard of care) based on the ICU bed they are assigned. Patient data will be collected until discharge.

NCT04367831 COVID-19 Venous Thromboses Arterial Thrombosis Drug: Enoxaparin Prophylactic Dose Drug: Heparin Infusion Drug: Heparin SC Drug: Enoxaparin/Lovenox Intermediate Dose
MeSH:Thrombosis Thromboembolism Venous Thrombosis
HPO:Deep venous thrombosis Thromboembolism Venous thrombosis

Primary Outcomes

Description: Composite of being alive and without clinically-relevant venous or arterial thrombotic events at discharge from ICU (without transfer to another ICU or palliative care unit/hospice) or at 30 days (if ICU duration lasted 30 days or longer).

Measure: Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU

Time: Discharge from ICU or 30 days

Secondary Outcomes

Description: Composite of being alive and without clinically-relevant venous or arterial thrombotic events at discharge from ICU (without transfer to another ICU or palliative care unit/hospice) or at 30 days (if ICU duration lasted 30 days or longer).

Measure: Total Number of Patients with In hospital Clinically Relevant Venous or Arterial Thrombotic Events

Time: Discharge from hospital or 30 days

Description: Length of stay measured in days.

Measure: ICU Length of Stay

Time: Discharge from ICU or 30 days

Description: The impact of intermediate-dose anti-coagulation compared with prophylactic anti-coagulation on rates of acute kidney injury and renal recovery in the ICU will be measured with the total number of patients who need of renal replacement therapy in the ICU.

Measure: Total Number of Patients with the Need for Renal Replacement Therapy in the ICU

Time: Discharge from hospital or 30 days

Description: Major bleeding will be assessed by BARC criteria, also explored by International Society on Thrombosis and Haemostasis (ISTH) and Thrombolysis in Myocardial Infarction (TIMI) criteria.

Measure: Total Number of Patients with Major bleeding in the ICU

Time: Discharge from hospital or 30 days

Description: Length of stay measured in days.

Measure: Hospital Length of Stay

Time: Discharge from hospital or 30 days

6 Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE

Worldwide observational studies indicate a significant prothrombogenic effect associated with SARS-CoV-2 infection with a high incidence of venous thromboembolism (VTE), notably life-threatening pulmonary embolism. According to recommendations for acute medical illnesses, all COVID-19 hospitalized patients should be given VTE prophylaxis such as a low molecular weight heparin (LMWH). A standard prophylactic dose (eg. Enoxaparin 4000IU once daily) could be insufficient in obese patients and VTE has been reported in patients treated with a standard prophylactic dose. In COVID-19 patients, guidelines from several international societies confirm the existence of an hypercoagulability and the importance of thromboprophylaxis but the "optimal dose is unknown" and comparative studies are needed. In view of these elements, carrying out a trial comparing various therapeutic strategies for the prevention of VTE in hospitalized patients with COVID-19 constitutes a health emergency. Thus, we hypothesize that an increased prophylactic dose of weight-adjusted LMWH would be greater than a lower prophylactic dose of LMWH to reduce the risk of life-threatening VTE in hospitalized patients. The benefit-risk balance of this increase dose will be carefully evaluated because of bleeding complications favored by possible renal / hepatic dysfunctions, drug interactions or invasive procedures in COVID-19 patients. This multicenter randomized (1:1) open-label controlled trial will randomize hospitalized adults with COVID-19 infection to weight-adjusted prophylactic dose vs. lower prophylactic dose of LMWH.

NCT04373707 COVID Thrombosis Pulmonary Embolism Deep Vein Thrombosis Drug: Enoxaparin Drug: Enoxaparin
MeSH:Pulmonary Embolism Thrombosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis
HPO:Deep venous thrombosis Pulmonary embolism Thromboembolism Venous thrombosis

Primary Outcomes

Description: Risk of deep vein thrombosis or pulmonary embolism or venous thromboembolism-related death

Measure: Venous thromboembolism

Time: 28 days

Secondary Outcomes

Description: Risk of major bleeding defined by the ISTH

Measure: Major bleeding

Time: 28 days

Description: Risk of Major Bleeding and Clinically Relevant Non-Major Bleeding Defined by the ISTH

Measure: Major Bleeding and Clinically Relevant Non-Major Bleeding

Time: 28 days

Description: Risk of Venous Thromboembolism and Major Bleeding

Measure: Net Clinical Benefit

Time: 28 days and 2 months

Description: Risk of venous thrombosis at other sites: e.g. superficial vein, catheters, hemodialysis access, ECMO, splanchnic, encephalic, upper limb

Measure: Venous Thromboembolism at other sites

Time: 28 days

Description: Risk of arterial thrombosis at any sites

Measure: Arterial Thrombosis

Time: 28 days

Description: Risk of all-cause mortality

Measure: All-Cause Mortality

Time: 28 days and 2 months

Description: Identification of associations between the risk of venous thromboembolism and clinical (eg. past medical history of thrombosis, cardiovascular risk factors, treatments, severity of COVID-19) and laboratory variables (e.g. D-dimers, fibrinogen, CRP) collected in the eCRF

Measure: Factors associated with the risk of venous thromboembolism

Time: 28 days

7 Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19

Severe COVID-19 patients at a high risk of venous thromboembolism. We studied patients in 2 intensive care units of university hospitals in Barcelona and Badalona, Spain. We performed a cut-off screening of deep venous thrombosis (DVT) with bilateral duplex ultrasound to 230 patients.

NCT04374617 COVID-19 Critical Illness Venous Thromboembolism Venous Thromboses Venous Thromboses, Deep Venous Thrombosis Pulmonary Pulmonary Embolism Pulmonary Embolism and Thrombosis Sars-CoV2 SARS-CoV Infection Diagnostic Test: Duplex ultrasound and Computed Tomography Angiography
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Pulmonary Embolism Thrombosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis Embolism and Thrombosis Critical Illness
HPO:Deep venous thrombosis Pulmonary embolism Thromboembolism Venous thrombosis

Primary Outcomes

Description: Patients with symptomatic pulmonary embolism confirmed on the CT-angiography and those with a swollen limb and confirmed deep venous thrombosis on compression ultrasound were considered to have "symptomatic venous thromboembolisms". The remaining patients with positive limb ultrasound or CT-angiography were considered to have "asymptomatic venous thrombembolism"

Measure: Venous thromboembolisms

Time: 7 days

Secondary Outcomes

Description: Deaths from all causes during the follow-up

Measure: Deaths

Time: 7 days

8 Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial

The OVID study will show whether prophylactic-dose enoxaparin improves survival and reduces unplanned hospitalizations in ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.

NCT04400799 COVID-19 Pulmonary Embolism, Deep Vein Thrombosis Drug: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml
MeSH:Pulmonary Embolism Thrombosis Embolism Venous Thrombosis
HPO:Deep venous thrombosis Pulmonary embolism Venous thrombosis

Primary Outcomes

Measure: hospitalizations

Time: 30 days

Measure: all-cause death

Time: 30 days

Secondary Outcomes

Description: including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke

Measure: Number of cardiovascular events

Time: within 14 days, 30 days, and 90 days of randomization

Measure: any hospitalizations

Time: within 14 days, 30 days, and 90 days of randomization

Measure: all-cause death

Time: within 14 days, 30 days, and 90 days of randomization

Description: measured by number of cardiovascular events, and major bleeding

Measure: Net clinical benefit

Time: within 14 days, 30 days, and 90 days of enrolment.

Description: ISTH criteria, in-hospital diagnosis

Measure: Disseminated intravascular coagulation

Time: within 14 days, 30 days, and 90 days of enrolment

9 Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic

The purpose of this study is to investigate the prevalence of venous thromboembolism in a regional health care system (Region Östergötland, Sweden) before and during the SARS-COV-2 pandemic. In a retrospective observational study, we will review patient data, diagnostic data and treatment data over a three-month period since the onset of the SARS-COV-2 pandemic. This data will be compared with data from the corresponding time frame during the years 2015 to 2019.

NCT04400877 COVID-19 Venous Thromboembolism Pulmonary Embolism Deep Vein Thrombosis SARS-CoV 2 Diagnostic Test: Diagnostic examination for venous thromboembolism
MeSH:Pulmonary Embolism Thrombosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis
HPO:Deep venous thrombosis Pulmonary embolism Thromboembolism Venous thrombosis

Primary Outcomes

Measure: Is there an increased prevalence of venous thromboembolism in a regional healthcare system in Sweden during the SARS-CoV-2 pandemic?

Time: March to May in 2020

Measure: Is a SARS-CoV-2-infection an isolated risk factor for thromboembolism?

Time: March to May in 2020

Secondary Outcomes

Measure: Are there geographic differences in the prevalence of venous thromboembolism within the healthcare system?

Time: March to May in 2020

Measure: Is venous thromboembolism associated with increased mortality adjusted for relevant comorbidities?

Time: March to May in 2020

Measure: How long is the time between symptom onset of the SARS-CoV-2-infection and any subsequent venous thromboembolism?

Time: March to May in 2020

Measure: Is treatment with prophylactic antithrombotic or anticoagulant treatment associated with increased survival?

Time: March to May in 2020

10 High Prevalence of Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology

Severe SARS-CoV-2 infection, responsible of COVID-19, is accompanied by many venous thromboembolic events. Antithrombotic treatment is the cornerstone of management of many neurovascular diseases (NVDs) and the benefit-risk ratio is crucial to avoid hemorrhagic complications. Therefore, in non-severe COVID-19 patients affected by NVDs, the diagnostic of deep venous thrombosis (DVT) is challenging. Using bedside Doppler ultrasonography (DUS) of lower limbs, this study investigated the rates of DVT in these patients in stroke unit.

NCT04452422 Deep Venous Thrombosis
MeSH:Thrombosis Venous Thrombosis
HPO:Deep venous thrombosis Venous thrombosis

Primary Outcomes

Measure: Number of cumulated deep venous thrombosis among the hospitalization

Time: Day 7 after admisssion


HPO Nodes